Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: How do fixed-location injections compare with trigger point-focused injections?

Pain Medicine

Volumn 12, Issue 11, 2011, Pages 1607-1614

  Benecke, Reiner ^a   Heinze, Axel ^b   Reichel, Gerhard ^c   Hefter, Harald ^d   Göbel, Hartmut ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Kiel Pain and Headache Centre   (Germany)

^c Internal Medicine Department   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Botulinum type A toxin; Injection technique; Myofascial trigger points; Upper back myofascial pain

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ANALGESIA; ARTICLE; BACKACHE; BONE DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEAD; HUMAN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYOFASCIAL PAIN; NECK MUSCLE; NECK PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; TREATMENT RESPONSE; TRIGGER POINT;

EID: 81855213072     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01163.x     Document Type: Article

References (29)

1. Fischer AA. New developments in diagnosis of myofascial pain and fibromyalgia. Phys Med Rehabil Clin N Am 1997;8:1-27.
2. Yunus MB, Kalyan-Raman UP, Kalyan-Raman K. Primary fibromyalgia syndrome and myofascial pain syndrome: Clinical features and muscle pathology. Arch Phys Med Rehabil 1988;69:451-4.
3. Simons DG. Myofascial Pain Syndromes Due to Trigger Points. St Louis, MO: Mosby; 1988.
4. Simons DG. Referred Phenomena of Myofascial Trigger Points. Amsterdam: Elsevier; 1993.
5. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993;18:1803-7.
6. Simons DG. Clinical and etiological update of myofascial pain from trigger points. J Musculoskelet Pain 1996;4:93-121.
7. Quintner JL, Cohen ML. Referred pain of peripheral nerve origin: An alternative to the "myofascial pain" construct. Clin J Pain 1994;10:243-51.
8. Wall PD, Melzack R. The Textbook of Pain. Edinburgh: Churchill Livingstone; 1994.
9. Wheeler AH. Myofascial pain disorders: Theory to therapy. Drugs 2004;64:45-62.
10. Baldry P. Management of myofascial trigger point pain. Acupunct Med 2002;20:2-10.
11. Cordivari C, Misra VP, Catania S, Lees AJ. New therapeutic indications for botulinum toxins. Mov Disord 2004;19(suppl 8):S157-61.
12. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 2004;107:125-33.
13. Acquadro MA, Borodic GE. Botulinum toxin efficacy for the treatment of pain. J Clin Anesth 2005;17:328-30.
14. Dressler D, Adib Saberi F. Botulinum toxin: Mechanisms of action. Eur Neurol 2005;53:3-9.
15. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum a toxin effects on rat jaw muscle spindles. Acta Otolaryngol (Stockh) 1993;113:400-4.
16. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-a injection. Muscle Nerve 1996;19:488-96.
17. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-9.
18. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23:1662-6.
19. Porta M. A comparative trial of botulinum toxin type a and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85:101-5.
20. Felber ES. Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006;106:609-14.
21. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type a toxin complex treatment (dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006;125:82-8.
22. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719.
23. Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type a toxin. Biologicals 2003;31:265-76.
24. Kamanli A, Kaya A, Ardicoglu O, etal. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-11.
25. Graboski CL, Gray DS, Burnham RS. Botulinum toxin a versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005;118:170-5.
26. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin a in chronic myofascial pain. Neurology 2006;67:241-5.
27. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: A double-blind, randomized, and controlled crossover trial. Clin J Pain 2006;22:90-6.
28. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type a. Anesthesiology 2005;103:377-83.
29. Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: A randomized, double-blind study. Pain Med 2009;10(6):1012-7.